Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Allison E B Chang, Andrew J Piper-Vallillo, Raymond H Mak, Michael Lanuti, Alona Muzikansky, Julia Rotow, Pasi A Jänne, Mari Mino-Kenudson, Scott Swanson, Cameron D Wright, David Kozono, Paul Marcoux, Zofia Piotrowska, Lecia V Sequist, Henning Willers
BACKGROUND: The role of tyrosine kinase inhibitors (TKIs) in early-stage and metastatic oncogene-driven non-small cell lung cancer (NSCLC) is established, but it remains unknown how best to integrate TKIs with concurrent chemoradiotherapy (cCRT) in locally advanced disease. The phase 2 ASCENT trial assessed the efficacy and safety of afatinib and cCRT with or without surgery in locally advanced epidermal growth factor receptor (EGFR)-mutant NSCLC. PATIENTS AND METHODS: Adults ≥18 years with histologically confirmed stage III (AJCC 7th edition) NSCLC with activating EGFR mutations were enrolled at Mass General and Dana-Farber/Brigham Cancer Centers, Boston, Massachusetts...
May 18, 2024: Oncologist
#2
JOURNAL ARTICLE
Emily Connell, Émilie Gerard, Bénédicte Oules, Florence Brunet-Possenti, Anouck Lamoureux, Hugo Bonnefille, Sorilla Mary-Prey, Ana Carrasquilla, Stéphane Mouret, Nora Kramkimel, Candice Lesage, Pierre-Emmanuel Stoebner, Axel Bartoli, Sandrine Monestier, Florian Correard, Audrey Gros, Arnaud Jeanson, L'Houcine Ouafik, Caroline Gaudy-Marqueste, Pascale Tomasini, Julie Charles, Mona Amini-Adle, Nausicaa Malissen
BACKGROUND: Only a fraction of patients with metastatic melanoma derive durable benefit from approved treatments. The clinical impact of personalized medicine strategies for melanoma, apart from BRAF, NRAS, or CKIT targeting, has rarely been reported. MATERIALS AND METHODS: By means of the Group of Cutaneous Oncology of the French Society of Dermatology, we retrospectively included all patients with advanced melanoma aged 18 years and older for whom molecular testing identified one or more actionable molecular alterations and who accordingly received molecularly matched therapy...
May 18, 2024: Oncologist
#3
JOURNAL ARTICLE
Martín Angel, Mutlu Demiray, Umut Dişel, João Passos
Genomic profiling and other new technologies have increased the volume and complexity of information available for guiding clinical decision-making in precision oncology. Consequently, there is a need for multidisciplinary expert teams, in the form of molecular tumor boards (MTBs), who can translate this information into a therapeutic plan, including matching patients to suitable clinical trials. Virtual MTBs (vMTBs) can help to overcome many of the challenges associated with in-person MTBs, such as limited time availability, access to appropriate experts or datasets, or interactions between institutions...
May 18, 2024: Oncologist
#4
JOURNAL ARTICLE
Jiaqi Wang, Qianqian Xu, Ziyang Xuan, Yuting Mao, Xi Tang, Ke Yang, Fahuan Song, Xin Zhu
OBJECTIVE: Patients with radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC; RAIR-DTC) have a poor prognosis. The aim of this study was to provide new insights and possibilities for the diagnosis and treatment of RAIR-DTC. METHODS: The metabolomics of 24 RAIR-DTC and 18 non-radioiodine-refractory (NonRAIR) DTC patients samples were analyzed by liquid chromatograph-mass spectrometry. Cellular radioiodine uptake was detected with γ counter. Sodium iodide symporter (NIS) expression and thyroid stimulating hormone receptor (TSHR) were measured by Western blot analysis...
May 18, 2024: Oncologist
#5
RANDOMIZED CONTROLLED TRIAL
Nicola Mills, Nicola Farrar, Barbara Warnes, Kate E Ashton, Rosie Harris, Chris A Rogers, Eric Lim, Daisy Elliott
OBJECTIVES: Recruiting to randomised trials is often challenging particularly when the intervention arms are markedly different. The Mesothelioma and Radical Surgery 2 randomised controlled trial (RCT) compared standard chemotherapy with or without (extended) pleurectomy decortication surgery for malignant pleural mesothelioma. Anticipating recruitment difficulties, a QuinteT Recruitment Intervention was embedded in the main trial phase to unearth and address barriers. The trial achieved recruitment to target with a 4-month COVID-19 pandemic-related extension...
May 16, 2024: BMJ Open
#6
REVIEW
Linda R Weber
Trust in one's physician drives positive health practices. However, the conceptualization and subsequent operationalization of trust have become clouded due to the multitude of approaches that have resulted in several different measures with varied dimensions and indicators. The objectives of this scoping review were: 1) to discover any new developments in the measurement of trust, 2) to identify those measures of trust, whether newly created or refined in the last ten years, that have known reliability and validity, and 3) to compare those instruments' conceptualizations, dimensions, and indicators...
2024: PloS One
#7
EDITORIAL
J Harvey Turner
On stage, and in real life, timing is critical for success. Theranostic cancer care epitomizes the central role of timing in the evolution of efficacious molecular targeted radioligand therapy and its incorporation into routine clinical practice of oncology. Nuclear medicine has returned to its therapeutic roots, having been founded as a medical specialty, over three-quarters of a century ago, with radioiodine therapy of thyroid cancer. The very recent oncologist acceptance of 68 Ga/177 Lu/225 Ac-PSMA effectiveness in treating prostate cancer has re-established the role of the physician in nuclear medicine...
May 17, 2024: Cancer Biotherapy & Radiopharmaceuticals
#8
Alexandra J Lamacki, Caroline Montag, Elizabeth Kertowidjojo, S Diane Yamada, Katherine C Kurnit
INTRODUCTION: Primary lymphomas of the gynecologic tract are a rare pathology that may present with typical gynecologic symptoms. Unlike other gynecologic malignancies, surgical management is not considered an essential part of the treatment regimen for gynecologic lymphomas but may be required for diagnosis. The purpose of this series is to report on symptom presentation and management from the gynecologic specialist's perspective. METHODS: Records from an institutional pathology database identified patients diagnosed with primary gynecologic lymphoma between 1993 and 2023...
June 2024: Gynecologic Oncology Reports
#9
Jihane Derfoufi, Mouhsine Omari, Younesse Najioui, Anass Haloui, Ouissam Al Jarroudi, Amal Bennani, Sami Aziz Brahmi, Said Afqir
Epithelioid hemangioendothelioma (EHE) is an extremely rare vascular tumor, which can pose a diagnostic dilemma. It affects women more than men and is mainly found in the liver, lung, and bone. To date, there are no known predisposing factors. Limited data are available on the management of EHE at metastatic stages. The only optimal treatments to prevent metastatic dissemination are surgical resection and amputation in addition to radiotherapy at early stages. The oncologist in this rare entity plays an important role in the guided and standardized management of this disease, especially for advanced stages...
April 2024: Curēus
#10
JOURNAL ARTICLE
Ullas Batra, Shrinidhi Nathany, Swarsat Kaushik Nath, Joslia T Jose, Trapti Sharma, Preeti P, Sunil Pasricha, Mansi Sharma, Nevidita Arambam, Vrinda Khanna, Abhishek Bansal, Anurag Mehta, Kamal Rawal
BACKGROUND: The prognosis of lung carcinoma has changed since the discovery of molecular targets and their specific drugs. Somatic Epidermal Growth Factor Receptor ( EGFR ) mutations have been reported in lung carcinoma, and these mutant proteins act as substrates for targeted therapies. However, in a resource-constrained country like India, panel-based next-generation sequencing cannot be made available to the population at large. Additional challenges such as adequacy of tissue in case of lung core biopsies and locating suitable tumour tissues as a result of innate intratumoral heterogeneity indicate the necessity of an AI-based end-to-end pipeline capable of automatically detecting and learning more effective lung nodule features from CT images and predicting the probability of the EGFR -mutant...
May 2024: Lancet Reg Health Southeast Asia
#11
JOURNAL ARTICLE
Revathy Krishnamurthy
This article explores an oncologist's journey from emotional vulnerability to practised detachment. A transformative moment, prompted by a poignant photograph of a patient in a scarlet saree, confronts the author with the emotional intricacies of patient care. The narrative delves into the human stories woven into the medical landscape, capturing the delicate balance between clinical detachment and maintaining a genuine connection. It prompts reflection on the emotional dynamics within the decision-making fabric of healthcare...
2024: Indian Journal of Medical Ethics
#12
JOURNAL ARTICLE
Maureen E Canavan, Xiaoliang Wang, Mustafa S Ascha, Rebecca A Miksad, Timothy N Showalter, Gregory S Calip, Cary P Gross, Kerin B Adelson
IMPORTANCE: Two prominent organizations, the American Society of Clinical Oncology and the National Quality Forum (NQF), have developed a cancer quality metric aimed at reducing systemic anticancer therapy administration at the end of life. This metric, NQF 0210 (patients receiving chemotherapy in the last 14 days of life), has been critiqued for focusing only on care for decedents and not including the broader population of patients who may benefit from treatment. OBJECTIVE: To evaluate whether the overall population of patients with metastatic cancer receiving care at practices with higher rates of oncologic therapy for very advanced disease experience longer survival...
May 16, 2024: JAMA Oncology
#13
JOURNAL ARTICLE
David Chen, Rod Parsa, Andrew Hope, Breffni Hannon, Ernie Mak, Lawson Eng, Fei-Fei Liu, Nazanin Fallah-Rad, Ann M Heesters, Srinivas Raman
IMPORTANCE: Artificial intelligence (AI) chatbots pose the opportunity to draft template responses to patient questions. However, the ability of chatbots to generate responses based on domain-specific knowledge of cancer remains to be tested. OBJECTIVE: To evaluate the competency of AI chatbots (GPT-3.5 [chatbot 1], GPT-4 [chatbot 2], and Claude AI [chatbot 3]) to generate high-quality, empathetic, and readable responses to patient questions about cancer. DESIGN, SETTING, AND PARTICIPANTS: This equivalence study compared the AI chatbot responses and responses by 6 verified oncologists to 200 patient questions about cancer from a public online forum...
May 16, 2024: JAMA Oncology
#14
REVIEW
Aeryn Kangas-Dick, Muhammad Ali, Mariola Poss, Thaer Khoury, Kazuaki Takabe
Desmoid fibromatosis of the breast (also known as desmoid tumor of the breast) is a rare entity infrequently encountered by oncologists and surgeons caring for patients with breast disease. The current body of literature is highly reliant on case series and extrapolations from other sites of desmoid tumor-related disease. Much remains unclear regarding the pathological origins, natural history, and response to treatment of this condition. Traditional treatment strategies have centered on surgical resection, which may result in significantly disfiguring cosmetic and functional outcomes, frequent need for re-operation, and associated morbidity...
June 2024: World Journal of Oncology
#15
REVIEW
Mahira Lopes Rosa, Tomas Reinert, Maiane Maria Pauletto, Guilherme Sartori, Marcia Graudenz, Carlos Henrique Barrios
Breast cancer (BC) is the most common neoplasm in women worldwide and one of the leading causes of female death. The triple-negative subtype, characterized by the absence of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2), tends to occur in younger patients, be more aggressive and less differentiated. Furthermore, this subtype is considered the most immunogenic and associated with higher levels of tumor cell infiltration, mainly lymphocytes. Tumor-infiltrating lymphocytes (TILs) play a crucial role in the interaction of the host's immune system and cancer cells...
2024: Transl Breast Cancer Res
#16
REVIEW
Umberto Malapelle, Natasha Leighl, Alfredo Addeo, Dov Hershkovitz, Maximilian J Hochmair, Ola Khorshid, Florian Länger, Filippo de Marinis, Nir Peled, Brandon S Sheffield, Egbert F Smit, Santiago Viteri, Jürgen Wolf, Filippo Venturini, Richard M O'Hara, Christian Rolfo
Non-small cell lung cancer is a heterogeneous disease and molecular characterisation plays an important role in its clinical management. Next-generation sequencing-based panel testing enables many molecular alterations to be interrogated simultaneously, allowing for comprehensive identification of actionable oncogenic drivers (and co-mutations) and appropriate matching of patients with targeted therapies. Despite consensus in international guidelines on the importance of broad molecular profiling, adoption of next-generation sequencing varies globally...
May 15, 2024: British Journal of Cancer
#17
JOURNAL ARTICLE
Dominic LaBella, Omaditya Khanna, Shan McBurney-Lin, Ryan Mclean, Pierre Nedelec, Arif S Rashid, Nourel Hoda Tahon, Talissa Altes, Ujjwal Baid, Radhika Bhalerao, Yaseen Dhemesh, Scott Floyd, Devon Godfrey, Fathi Hilal, Anastasia Janas, Anahita Kazerooni, Collin Kent, John Kirkpatrick, Florian Kofler, Kevin Leu, Nazanin Maleki, Bjoern Menze, Maxence Pajot, Zachary J Reitman, Jeffrey D Rudie, Rachit Saluja, Yury Velichko, Chunhao Wang, Pranav I Warman, Nico Sollmann, David Diffley, Khanak K Nandolia, Daniel I Warren, Ali Hussain, John Pascal Fehringer, Yulia Bronstein, Lisa Deptula, Evan G Stein, Mahsa Taherzadeh, Eduardo Portela de Oliveira, Aoife Haughey, Marinos Kontzialis, Luca Saba, Benjamin Turner, Melanie M T Brüßeler, Shehbaz Ansari, Athanasios Gkampenis, David Maximilian Weiss, Aya Mansour, Islam H Shawali, Nikolay Yordanov, Joel M Stein, Roula Hourani, Mohammed Yahya Moshebah, Ahmed Magdy Abouelatta, Tanvir Rizvi, Klara Willms, Dann C Martin, Abdullah Okar, Gennaro D'Anna, Ahmed Taha, Yasaman Sharifi, Shahriar Faghani, Dominic Kite, Marco Pinho, Muhammad Ammar Haider, Michelle Alonso-Basanta, Javier Villanueva-Meyer, Andreas M Rauschecker, Ayman Nada, Mariam Aboian, Adam Flanders, Spyridon Bakas, Evan Calabrese
Meningiomas are the most common primary intracranial tumors and can be associated with significant morbidity and mortality. Radiologists, neurosurgeons, neuro-oncologists, and radiation oncologists rely on brain MRI for diagnosis, treatment planning, and longitudinal treatment monitoring. However, automated, objective, and quantitative tools for non-invasive assessment of meningiomas on multi-sequence MR images are not available. Here we present the BraTS Pre-operative Meningioma Dataset, as the largest multi-institutional expert annotated multilabel meningioma multi-sequence MR image dataset to date...
May 15, 2024: Scientific Data
#18
JOURNAL ARTICLE
Hope S Rugo, Peter Schmid, Sara M Tolaney, Florence Dalenc, Frederik Marmé, Ling Shi, Wendy Verret, Anuj Shah, Mahdi Gharaibeh, Aditya Bardia, Javier Cortes
BACKGROUND: The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physician's choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) metastatic breast cancer (mBC). Here, we present health-related quality of life (HRQoL) patient-reported outcome (PRO) findings from this study. PATIENTS AND METHODS: Eligible adults with HR+/HER2- mBC who previously received a taxane, endocrine-based therapy, a CDK4/6 inhibitor, and 2-4 lines of chemotherapy were randomized 1:1 to receive SG or TPC until progression or unacceptable toxicity...
May 15, 2024: Oncologist
#19
JOURNAL ARTICLE
Iván Márquez-Rodas, Eva Muñoz Couselo, Juan F Rodríguez Moreno, Ana Mª Arance Fernández, Miguel Ángel Berciano Guerrero, Begoña Campos Balea, Luis de la Cruz Merino, Enrique Espinosa Arranz, Almudena García Castaño, Alfonso Berrocal Jaime
Cutaneous melanoma incidence is rising. Early diagnosis and treatment administration are key for increasing the chances of survival. For patients with locoregional advanced melanoma that can be treated with complete resection, adjuvant-and more recently neoadjuvant-with targeted therapy-BRAF and MEK inhibitors-and immunotherapy-anti-PD-1-based therapies-offer opportunities to reduce the risk of relapse and distant metastases. For patients with advanced disease not amenable to radical treatment, these treatments offer an unprecedented increase in overall survival...
May 15, 2024: Clinical & Translational Oncology
#20
JOURNAL ARTICLE
Yasuo Kosugi, Keisuke Sasai, Naoya Murakami, Tatsuki Karino, Yoichi Muramoto, Terufumi Kawamoto, Masaki Oshima, Noriyuki Okonogi, Jun Takatsu, Kotaro Iijima, Shuhei Karube, Akira Isobe, Naoya Hara, Mitsuhisa Fujimaki, Shinichi Ohba, Fumihiko Matsumoto, Koji Murakami, Naoto Shikama
PURPOSE: To determine the efficacy and safety of target volume determination by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) for intensity-modulated radiation therapy (IMRT) for locally advanced head and neck squamous cell carcinoma (HNSCC) extending into the oral cavity or oropharynx. METHODS: We prospectively treated 10 consecutive consenting patients with HNSCC using IMRT, with target volumes determined by PET-CT. Gross tumor volume (GTV) and clinical target volume (CTV) at the oral level were determined by two radiation oncologists for CT, magnetic resonance imaging (MRI), and PET-CT...
March 15, 2024: EJNMMI Rep
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
